Literature DB >> 27279108

Monocrotaline-induced pulmonary hypertension with sufficient tricuspid regurgitation in a rat model.

Fuminobu Ishikura1, Ryoko Azakami2, Toshihiko Asanuma2, Shintaro Beppu3.   

Abstract

BACKGROUND AND
PURPOSE: It is well known that monocrotaline (MCT) induces pulmonary hypertension (PH) in rats. This model is very useful for understanding the physiology of PH and developing treatments for PH. However, it is very difficult to estimate pulmonary artery pressure (PAP) in this model. The purpose of this study is to establish a PH model with sufficient tricuspid regurgitation (TR) to evaluate PAP.
METHOD: We studied 17 male rats that received 15 injections of 5 mg/kg/day of MCT (PH) or vehicle (control). Three weeks after the first MCT injection, we measured left and right ventricular dimensions, the ratio of acceleration to ejection time in pulmonary flow, and the development of TR using an echocardiograph (SONOS5500) with a s12 probe (frequency: 5-12 MHz, frame rate: 120 Hz).
RESULTS: The right ventricular end-diastolic area in the PH group was significantly larger than that in the control group. The acceleration time/ejection time ratio and velocity time integral of the pulmonary artery in the PH group were smaller than those in the control group. In 78 % of rats in the PH group, sufficient TR was observed and estimated PAP was 75.4 ± 13.8 mmHg. There was a good correlation between PAP estimated by a Doppler method and directly measured right ventricular pressure (r = 0.94, P < 0.0001).
CONCLUSION: Fifteen injections of 5 mg/kg/day of MCT could induce PH with sufficient TR in rats. Transthoracic echocardiography could be used for monitoring the progress of PH in the rat model.

Entities:  

Keywords:  Monocrotaline; Pulmonary hypertension; Tricuspid regurgitation

Year:  2012        PMID: 27279108     DOI: 10.1007/s10396-012-0371-x

Source DB:  PubMed          Journal:  J Med Ultrason (2001)        ISSN: 1346-4523            Impact factor:   1.314


  16 in total

1.  The ratio of the atrial areas reflects the clinical status of patients with pulmonary arterial hypertension.

Authors:  Takashi Morishita; Katsumasa Miyaji; Izumi Akao; Keiji Fujita; Hiromi Nakayama; Kenichi Hisamatsu; Mitsuru Munemasa; Yoshihisa Fujimoto; Hiromi Matsubara
Journal:  J Med Ultrason (2001)       Date:  2009-08-15       Impact factor: 1.314

2.  Noninvasive measurement of right ventricular systolic pressure by combined color-coded and continuous-wave Doppler ultrasound.

Authors:  H P Hamer; B L Takens; J L Posma; K I Lie
Journal:  Am J Cardiol       Date:  1988-03-01       Impact factor: 2.778

3.  Noninvasive assessment of acute cardiopulmonary effects of an oral single dose of sildenafil in patients with idiopathic pulmonary hypertension.

Authors:  Neda Behzadnia; Katayoun Najafizadeh; Babak Sharif-Kashani; Davoud Oulad Dameshghi; Payman Shahabi
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

4.  Echocardiographic detection of pulmonary hypertension in anesthetized rats.

Authors:  C M Cottrill; G L Johnson; M N Gillespie
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1988-05

5.  Doppler tissue imaging in assessment of pulmonary hypertension-induced right ventricle dysfunction.

Authors:  Julien Boissiere; Mathieu Gautier; Marie-Christine Machet; Gilles Hanton; Pierre Bonnet; Veronique Eder
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-07-29       Impact factor: 4.733

6.  EndothelinA receptor blockade improves nitric oxide-mediated vasodilation in monocrotaline-induced pulmonary hypertension.

Authors:  S Prié; D J Stewart; J Dupuis
Journal:  Circulation       Date:  1998-06-02       Impact factor: 29.690

7.  Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension.

Authors:  T Miyauchi; R Yorikane; S Sakai; T Sakurai; M Okada; M Nishikibe; M Yano; I Yamaguchi; Y Sugishita; K Goto
Journal:  Circ Res       Date:  1993-11       Impact factor: 17.367

8.  Alterations of growth factor transcripts in rat lungs during development of monocrotaline-induced pulmonary hypertension.

Authors:  S S Arcot; D W Lipke; M N Gillespie; J W Olson
Journal:  Biochem Pharmacol       Date:  1993-09-14       Impact factor: 5.858

9.  Serial noninvasive assessment of progressive pulmonary hypertension in a rat model.

Authors:  John E Jones; Lisa Mendes; M Audrey Rudd; Giulia Russo; Joseph Loscalzo; Ying-Yi Zhang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-07       Impact factor: 4.733

10.  Changes in pulmonary structure and function induced by monocrotaline intoxication.

Authors:  F Ghodsi; J A Will
Journal:  Am J Physiol       Date:  1981-02
View more
  1 in total

1.  Pimobendan improves right ventricular myocardial contraction and attenuates pulmonary arterial hypertension in rats with monocrotaline-induced pulmonary arterial hypertension.

Authors:  Rieko Yoshiyuki; Telma Mary Nakata; Toshiharu Fukayama; Lina Hamabe; Hsu Huai-Che; Shuji Suzuki; Noboru Machida; Ryuji Fukushima; Ryou Tanaka
Journal:  J Med Ultrason (2001)       Date:  2013-08-24       Impact factor: 1.314

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.